Concepedia

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

Anas Younes, Armando Santoro, Margaret A. Shipp, Pier Luigi Zinzani, John M. Timmerman, Stephen M. Ansell, Philippe Armand, Michelle A. Fanale, Voravit Ratanatharathorn, John Kuruvilla,

The Lancet Oncology · 2016 · 924 citations · 18 references

DOIFull text

Open access

Concepts

References

18

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text

, , +17

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text

, , +17

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Gordon J. Freeman, Andrew J. Long, Yoshiko Iwai et al. · The Journal of Experimental Medicine · 2000 · 5.2K citations · Full text

, , +17

Revised Response Criteria for Malignant Lymphoma

Bruce D. Cheson, Beate Pfistner, Malik E. Juweid et al. · Journal of Clinical Oncology · 2007 · 4.4K citations · Full text

, , +15

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello et al. · New England Journal of Medicine · 2014 · 3.5K citations · Full text

, , +17